Results 121 to 130 of about 141,132 (265)
Bipartisan-cited science is rare, unevenly distributed, and disproportionately influential. [PDF]
Furnas AC, Wang D.
europepmc +1 more source
Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane +19 more
wiley +1 more source
Free Neuropathology: A bibliometric impact analysis. [PDF]
Haase G +3 more
europepmc +1 more source
ABSTRACT Objective Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker‐defined synucleinopathy.
Daniel Weintraub +24 more
wiley +1 more source
Persuasive technologies for modifying food habits: a review of mindless, reflective, and social approaches to eating behavior change. [PDF]
Rapp A.
europepmc +1 more source
Growth: With or Without Scale Effects? [PDF]
December 15, 1998 -- Version 1.0 The property that ideas are nonrivalrous leads to a tight link between idea-based growth models and increasing returns to scale.
Charles I. Jones
core
ABSTRACT Background Collaterals are crucial factors that influence the infarct growth rate (IGR). We aimed to determine whether a comprehensive multimodal collateral score (MCS), incorporating collateral assessment at the arterial, tissue, and venous levels, is associated with functional independence and provides incremental prognostic value over ...
Giorgio Busto +12 more
wiley +1 more source
School-Based Educational Interventions for Improving Knowledge of Back Health, Ergonomics and Postural Behaviour of School Children Aged 4-18 Years: A Best Evidence Systematic Review. [PDF]
Bettany-Saltikov J +8 more
europepmc +1 more source

